e-learning
resources
Munich 2006
Monday 04.09.2006
Blood gas workshop
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
How do we interpret the results?
J. Roca (Barcelona, Spain)
Source:
Annual Congress 2006 - Blood gas workshop
Session:
Blood gas workshop
Session type:
Symposium
Number:
2061
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Roca (Barcelona, Spain). How do we interpret the results?. Annual Congress 2006 - Blood gas workshop
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Nasal high-Flow (NHF) improves ventilation in patients with interstitial lung disease (ILD)
Noninvasive negative pressure ventilation improves survival of COPD patients with exercise desaturation
Cerebral oxygenation in lowlanders with COPD spending a night at 2590m
Related content which might interest you:
How do we interpret the sample data?
Source: International Congress 2014 – PG17 Lung cancer: the issue with the tissue
Year: 2014
How to interpret microbiological results
Source: International Congress 2014 – PG08 The management of non-CF bronchiectasis: from childhood to adulthood
Year: 2014
What have we learn from rebiospy studies?
Source: ERS Research Seminar
Year: 2015
How to share the results of pulmonary function testing with clinicians?
Source: Eur Respir J 2006; 28: Suppl. 50, 863s
Year: 2006
Is there a need for ongoing support for the interpretation of spirometry results by general practitioners?
Source: Eur Respir J 2006; 28: Suppl. 50, 740s
Year: 2006
When to apply which bronchial challenge test and interpretation of the results
Source: Annual Congress 2013 –New ATS/ERS recommendations for bronchial challenge testing
Year: 2013
How can real-world data be used to improve outcomes?
Source: Research Seminar 2021 – Unravelling severe exacerbations of COPD – CICERO an ERS CRC
Year: 2021
The way forward: how to link real-life situations and clinical trial results
Source: Annual Congress 2013 - Lunchtime Session "Tiotropium soft mist inhaler and mortality in COPD: results of the TIOSPIR clinical trial"
Year: 2013
Why don't patients follow the rules? Understanding the motivation behind behavioural change
Source: Annual Congress 2013 –PG8 How to encourage compliance with therapy
Year: 2013
What makes large epidemiological studies comparable?
Source: Eur Respir J 2010; 36: 720-721
Year: 2010
New methods: what do they tell us? Fluctuation analysis of lung function
Source: Eur Respir Mon; 2010: 47: 310–324
Year: 2010
Are estimations of radiomic image markers dispensable due to recent deep learning findings?
Source: Eur Respir J, 54 (2) 1901185; 10.1183/13993003.01185-2019
Year: 2019
COVID-19 phenotypes: leading or misleading?
Source: Eur Respir J, 56 (2) 2002195; 10.1183/13993003.02195-2020
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept